Whitehawk Therapeutics (WHWK) Non-Current Assets (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Non-Current Assets data on file, last reported at $1.7 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.7 million, up 21.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (down 72.16% YoY), and the FY2025 annual result was $1.8 million, down 79.88% from the prior year.
• Non-Current Assets declined to $1.7 million in Q1 2026 per WHWK's latest filing, from $1.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $9.0 million in Q4 2024 and troughed at $1.4 million in Q1 2025.
• A 5-year average of $5.3 million and a median of $5.7 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 14503.42% in 2022, then plunged 83.67% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $4.2 million in 2022, then jumped by 86.24% to $7.8 million in 2023, then advanced by 15.25% to $9.0 million in 2024, then slumped by 79.88% to $1.8 million in 2025, then decreased by 7.37% to $1.7 million in 2026.
• Business Quant data shows WHWK's Non-Current Assets at $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $2.0 million in Q3 2025.